|
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) Évaluation DCF
CN | Healthcare | Biotechnology | SHH
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) Bundle
Conçu pour la précision, notre calculatrice DCF (688513SS) vous permet d'évaluer l'évaluation de Chengdu Easton Biopharmaceuticals Co., Ltd. à l'aide de données financières réelles, avec une flexibilité complète pour modifier tous les paramètres essentiels pour des projections améliorées.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 947.2 | 921.9 | 1,022.9 | 1,170.5 | 1,117.1 | 1,167.8 | 1,220.8 | 1,276.2 | 1,334.1 | 1,394.6 |
| Revenue Growth, % | 0 | -2.67 | 10.96 | 14.43 | -4.56 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 |
| EBITDA | 144.0 | 233.9 | 281.3 | 324.0 | 319.9 | 290.5 | 303.7 | 317.5 | 331.9 | 347.0 |
| EBITDA, % | 15.21 | 25.37 | 27.5 | 27.68 | 28.64 | 24.88 | 24.88 | 24.88 | 24.88 | 24.88 |
| Depreciation | 28.0 | 33.9 | 33.8 | 59.7 | 74.7 | 50.7 | 53.0 | 55.4 | 58.0 | 60.6 |
| Depreciation, % | 2.95 | 3.68 | 3.3 | 5.1 | 6.69 | 4.34 | 4.34 | 4.34 | 4.34 | 4.34 |
| EBIT | 116.1 | 200.0 | 247.5 | 264.3 | 245.2 | 239.8 | 250.7 | 262.0 | 273.9 | 286.4 |
| EBIT, % | 12.26 | 21.69 | 24.19 | 22.58 | 21.95 | 20.53 | 20.53 | 20.53 | 20.53 | 20.53 |
| Total Cash | 404.1 | 1,625.3 | 1,504.5 | 1,347.3 | 1,523.0 | 1,033.9 | 1,080.8 | 1,129.8 | 1,181.1 | 1,234.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 149.5 | 151.1 | 126.7 | 180.9 | 177.7 | 177.3 | 185.4 | 193.8 | 202.6 | 211.8 |
| Account Receivables, % | 15.78 | 16.39 | 12.39 | 15.46 | 15.91 | 15.19 | 15.19 | 15.19 | 15.19 | 15.19 |
| Inventories | 60.4 | 84.0 | 103.7 | 140.9 | 161.0 | 121.6 | 127.1 | 132.9 | 138.9 | 145.2 |
| Inventories, % | 6.38 | 9.11 | 10.14 | 12.03 | 14.41 | 10.41 | 10.41 | 10.41 | 10.41 | 10.41 |
| Accounts Payable | 51.2 | 122.7 | 203.9 | 156.9 | 135.1 | 149.8 | 156.6 | 163.7 | 171.2 | 178.9 |
| Accounts Payable, % | 5.4 | 13.31 | 19.93 | 13.4 | 12.1 | 12.83 | 12.83 | 12.83 | 12.83 | 12.83 |
| Capital Expenditure | -95.4 | -198.8 | -256.3 | -339.3 | -175.3 | -236.8 | -247.5 | -258.7 | -270.5 | -282.7 |
| Capital Expenditure, % | -10.07 | -21.56 | -25.05 | -28.99 | -15.69 | -20.27 | -20.27 | -20.27 | -20.27 | -20.27 |
| Tax Rate, % | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 |
| EBITAT | 108.8 | 179.0 | 233.0 | 248.7 | 230.0 | 223.1 | 233.3 | 243.8 | 254.9 | 266.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -117.4 | 60.4 | 96.4 | -169.4 | 90.9 | 91.5 | 32.0 | 33.5 | 35.0 | 36.6 |
| WACC, % | 5.25 | 5.24 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 201.4 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 38 | |||||||||
| Terminal Value | 1,678 | |||||||||
| Present Terminal Value | 1,300 | |||||||||
| Enterprise Value | 1,501 | |||||||||
| Net Debt | -561 | |||||||||
| Equity Value | 2,062 | |||||||||
| Diluted Shares Outstanding, MM | 120 | |||||||||
| Equity Value Per Share | 17.20 |
What You Will Receive
- Comprehensive Financial Model: Leverage Chengdu Easton Biopharmaceuticals' (688513SS) actual data for accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other essential metrics to suit your analysis.
- Real-Time Calculations: Automated updates allow you to view results instantly as you alter inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation at an investor level.
- Flexible and Reusable: Designed for adaptability, facilitating repeated application for in-depth forecasts.
Key Features
- Pre-Loaded Data: Chengdu Easton Biopharmaceuticals’ historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Instant Results: Watch Chengdu Easton Biopharmaceuticals' intrinsic value recalculate instantly.
- Clear Visual Outputs: Dashboard charts present valuation results and essential metrics.
- Built for Accuracy: A professional tool tailored for analysts, investors, and finance professionals.
How It Functions
- Download: Obtain the pre-formatted Excel file containing financial data for Chengdu Easton Biopharmaceuticals Co., Ltd. (688513SS).
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch the intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Generate various projections and compare the results instantly.
- Make Decisions: Leverage the valuation insights to inform your investment approach.
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your specific analysis.
- Real-Time Updates: Instantly observe changes in Chengdu Easton Biopharmaceuticals' valuation as you tweak inputs.
- Pre-Loaded Data: Comes equipped with Chengdu Easton Biopharmaceuticals' actual financial metrics for swift evaluations.
- Relied on by Experts: Valued by investors and analysts for making well-informed choices.
Who Can Benefit from This Product?
- Investors: Accurately assess the fair value of Chengdu Easton Biopharmaceuticals Co., Ltd. (688513SS) prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for comprehensive financial reporting and analysis.
- Consultants: Efficiently customize the template for client valuation reports.
- Entrepreneurs: Acquire knowledge of financial modeling techniques employed by leading biopharmaceutical companies.
- Educators: Implement this resource as a teaching aid to illustrate valuation methods.
Contents of the Template
- Historical Data: Provides past financial performance and baseline forecasts for Chengdu Easton Biopharmaceuticals Co., Ltd. (688513SS).
- DCF and Levered DCF Models: Comprehensive templates for calculating the intrinsic value of Chengdu Easton Biopharmaceuticals Co., Ltd. (688513SS).
- WACC Sheet: Ready-to-use calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize key metrics such as growth rates, EBITDA percentages, and CAPEX assumptions.
- Quarterly and Annual Statements: An extensive overview of Chengdu Easton Biopharmaceuticals Co., Ltd. (688513SS) financial statements.
- Interactive Dashboard: Dynamically visualize valuation results and future projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.